» Articles » PMID: 39596525

Biallelic Germline Frameshift Mutations Associated with Isolated Diminished Ovarian Reserve

Abstract

The use of next-generation sequencing (NGS) has recently enabled the discovery of genetic causes of primary ovarian insufficiency (POI) with high genetic heterogeneity. In contrast, the causes of diminished ovarian reserve (DOR) remain poorly understood. Here, we identified by NGS and whole exome sequencing (WES) the cause of isolated DOR in a 14-year-old patient. Two frameshift mutations in () were found: in exon 8 (c.470_471del; p.Ser157Ter) and in exon 11 (c.791_794del, p.Ser264MetfsTer33). Unexpectedly, the patient presented no signs of Fanconi anemia (FA), i.e., no developmental abnormalities or indications of bone marrow failure. However, high chromosomal fragility was found in the patient's cells, consistent with an FA diagnosis. RT-PCR and Western-blot analysis support the fact that the c. 791_794del allele is transcribed and translated into a shorter protein (del11q), while no expression of the full-length BRCA1 protein was found. DNA damage response (DDR) studies after genotoxic agents demonstrate normal activation of the early stages of the DDR and FANC/BRCA pathway. This is consistent with the maintenance of residual repair activity for the del11q BRCA1 isoform. Our observation is the first implication of bi-allelic mutations in isolated ovarian dysfunction or infertility in humans, without clinical signs of FA, and highlights the importance of BRCA1 in ovarian development and function.

References
1.
Byrjalsen A, Steffensen A, Hansen T, Wadt K, Gerdes A . Classification of the spliceogenic c.4096+3A>G variant as likely benign based on cosegregation data and identification of a healthy homozygous carrier. Clin Case Rep. 2017; 5(6):876-879. PMC: 5458035. DOI: 10.1002/ccr3.944. View

2.
Wang Y, Bernhardy A, Cruz C, Krais J, Nacson J, Nicolas E . The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin. Cancer Res. 2016; 76(9):2778-90. PMC: 4874568. DOI: 10.1158/0008-5472.CAN-16-0186. View

3.
Huhtaniemi I, Hovatta O, La Marca A, Livera G, Monniaux D, Persani L . Advances in the Molecular Pathophysiology, Genetics, and Treatment of Primary Ovarian Insufficiency. Trends Endocrinol Metab. 2018; 29(6):400-419. DOI: 10.1016/j.tem.2018.03.010. View

4.
Witus S, Zhao W, Brzovic P, Klevit R . BRCA1/BARD1 is a nucleosome reader and writer. Trends Biochem Sci. 2022; 47(7):582-595. PMC: 9189015. DOI: 10.1016/j.tibs.2022.03.001. View

5.
Fernandes G, Michelli R, Galvao H, Paula A, Pereira R, Andrade C . Prevalence of BRCA1/BRCA2 mutations in a Brazilian population sample at-risk for hereditary breast cancer and characterization of its genetic ancestry. Oncotarget. 2016; 7(49):80465-80481. PMC: 5348334. DOI: 10.18632/oncotarget.12610. View